229 related articles for article (PubMed ID: 24771259)
1. [Importance of pathology for therapy planning of testicular germ cell tumors].
Heidenreich A; Knüchel-Clarke R; Pfister D
Pathologe; 2014 May; 35(3):266-73. PubMed ID: 24771259
[TBL] [Abstract][Full Text] [Related]
2. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
3. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
[TBL] [Abstract][Full Text] [Related]
4. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
Paffenholz P; Pfister D; Heidenreich A
Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
[TBL] [Abstract][Full Text] [Related]
5. Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists.
Lobo J; Costa AL; Vilela-Salgueiro B; Rodrigues Â; Guimarães R; Cantante M; Lopes P; Antunes L; Jerónimo C; Henrique R
Hum Pathol; 2018 Dec; 82():113-124. PubMed ID: 30041024
[TBL] [Abstract][Full Text] [Related]
6. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
7. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
8. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
9. [Stage-specific treatment for testicular germ cell tumours].
Heidenreich A; Bokemeyer C; Souchon R
Urologe A; 2009 Apr; 48(4):377-85. PubMed ID: 19252891
[TBL] [Abstract][Full Text] [Related]
10. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
11. Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?
Scandura G; Wagner T; Beltran L; Alifrangis C; Shamash J; Berney DM
Mod Pathol; 2021 Apr; 34(4):834-841. PubMed ID: 33319858
[TBL] [Abstract][Full Text] [Related]
12. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
[TBL] [Abstract][Full Text] [Related]
13. Management of residual masses in testicular germ cell tumors.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Expert Rev Anticancer Ther; 2019 Apr; 19(4):291-300. PubMed ID: 30793990
[TBL] [Abstract][Full Text] [Related]
14. Management of residual non-retroperitoneal disease following chemotherapy for germ cell tumor.
Sadeghi N; Badalato GM; Kates M; McKiernan JM
Urol Oncol; 2011; 29(6):837-41. PubMed ID: 21489835
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
16. Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.
Kopp RP; Chevinsky M; Bernstein M; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2017 May; 103():154-160. PubMed ID: 27816603
[TBL] [Abstract][Full Text] [Related]
17. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
Fosså SD; Qvist H; Stenwig AE; Lien HH; Ous S; Giercksky KE
J Clin Oncol; 1992 Apr; 10(4):569-73. PubMed ID: 1312586
[TBL] [Abstract][Full Text] [Related]
18. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
[TBL] [Abstract][Full Text] [Related]
19. Late relapse (>2 years) on surveillance in stage I non-seminomatous germ cell tumours; predominant seminoma only histology.
Nolan L; Wheater M; Kirby J; Simmonds P; Mead G
BJU Int; 2010 Dec; 106(11):1648-51. PubMed ID: 20735393
[TBL] [Abstract][Full Text] [Related]
20. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
